Zila, Inc. (ZILA) is dedicated to the prevention, detection and treatment of oral cancer and other periodontal diseases. The company’s flagship product, ViziLite Plus, is designed for the early detection of oral abnormalities that often lead to cancer. It is recognized as the first and only medical device that has been cleared by the FDA for use in a population at an increased risk for oral cancer.
The company also designs, manufactures and markets an entire suite of proprietary products that are sold directly to dental professionals for periodontal disease. These products include the Rota-Dent powered toothbrush, the Pro-Select ultrasonic scaler for the prevention and treatment of periodontal disease, and Pro-Den RX fluorides, rinses and gels.
Over the past few years, Zila’s stock has been steadily drifting lower. It appears to have made a base slightly below $0.20 and is robustly moving up. In their stock alert, Beacon Equity commented, “With revenues of close to $10 million, margins at whopping 61% and cash in excess of $3 million, we think this stock is an absolute steal right now.
Let us hear your thoughts below: